Crinetics Pharmaceuticals
(NASDAQ) CRNX
Crinetics Pharmaceuticals Financials at a Glance
Market Cap
$8.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$18.07M
Net Income (TTM)
-$496.39M
EPS (TTM)
-$5.13
P/E Ratio
-16.27
Dividend
$0.00
Beta (Volatility)
1.19 (Average)
Dividend
$0.00
Beta (Volatility)
1.19 (Average)
Price
$83.51
Volume
14,338.501
Open
$83.58
Price
$83.51
Volume
14,338.501
Open
$83.58
Previous Close
$83.53
Daily Range
$83.43 - $83.63
52-Week Range
$25.83 - $83.63
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
1.19 (Average)
Price
$83.51
Volume
14,338.501
Open
$83.58
Previous Close
$83.53
Daily Range
$83.43 - $83.63
52-Week Range
$25.83 - $83.63
Estimated Earnings Date
Aug 4, 2026
CRNX News
CRNX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Crinetics Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
594
CEO
Scott R. Struthers, PhD
Website
www.crinetics.comHeadquarters
San Diego, CA 92121, US
CRNX Financials
Key Financial Metrics (TTM)
Gross Margin
98.89%
Operating Margin
-3020.32%
Net Income Margin
-2747.18%
Return on Equity
-43.96%
Return on Capital
-49.66%
Return on Assets
-35.42%
Earnings Yield
-6.15%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$8.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
105.44M
Volume
14.34K
Avg. Volume
2.58M
Financials (TTM)
Gross Profit
$17.87M
Operating Income
-$545.74M
EBITDA
-$492.08M
Operating Cash Flow
-$414.17M
Capital Expenditure
-$5.34M
Free Cash Flow
-$419.52M
Cash & ST Invst.
$1.29B
Total Debt
$47.86M
Crinetics Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$10.73M
+2873.4%
Gross Profit
$10.53M
+2818.0%
Gross Margin
98.14%
N/A
Market Cap
$8.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$14.83M
N/A
Employees
594
N/A
Net Income
-$127.85M
-32.1%
EBITDA
-$126.69M
-32.2%
Quarterly Fundamentals
Total Cash
$1.29B
+1.3%
Total Debt
$47.86M
-5.8%
Accounts Receivable
$5.68M
-22.3%
Inventory
$3.06M
N/A
Long Term Debt
$41.32M
-6.0%
Short Term Debt
$6.54M
-5.0%
Return on Assets
-35.42%
N/A
Return on Invested Capital
-41.03%
N/A
Free Cash Flow
-$125.52M
-40.0%
Operating Cash Flow
-$124.70M
-41.0%